Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. September 2021 16:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program -- BARDA Contract Now Valued at Up to ~$304M -- Development Milestones Specified for Future Procurements ...
23. September 2021 16:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021

BOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA® (omadacycline) clinical and microbiology programs are being...
09. September 2021 08:30 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
01. September 2021 16:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
18. August 2021 16:12 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
09. August 2021 16:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery...
04. August 2021 16:30 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
03. August 2021 16:30 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
02. August 2021 16:35 ET | Quelle: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
02. August 2021 16:30 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Vorherige Seite

Nächste Seite